Novavax Partners Secure Nuvaxovid Approvals for 2026-2027 Season

M&A · PartnershipRegulation
โดย PR Newswire·USEUJP·Read original
Summary · why it matters

Novavax's partners have received approvals for the XFG-adapted Nuvaxovid vaccine for the 2026-2027 vaccination season in the U.S., European Union, and Japan, positioning the company to earn royalties on net sales in these markets. The approvals, announced August 28, 2026, cover the protein-based, non-mRNA vaccine, which has demonstrated a favorable tolerability profile in Sanofi's Phase 4 COMPARE study. Novavax's largest partner, Sanofi, will lead commercial activities in most major markets, including an expanded U.S. campaign and launches in Germany, Canada, and other international markets from 2026 onward. Takeda, which commercializes Nuvaxovid in Japan, saw the vaccine become the second-most used COVID-19 vaccine there in the 2025-2026 season, with delivery volumes and site numbers increasing significantly year over year. Under the collaboration and license agreements, Novavax is eligible for ongoing royalties and annual milestones tied to regulatory approvals, without carrying its own commercial infrastructure.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 2 stocks
Novavax Inc
NVAX
▲ PositiveDemandrelevance

Approvals for Nuvaxovid in major markets secure royalties and milestones for Novavax.

Health Care▲ · 1 stocks
Sanofi SA
SAN
▲ PositiveDemandrelevance

Sanofi leads commercial activities for Nuvaxovid, expanding its vaccine portfolio and market reach.

© 2026 MarketDXNews